Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 16/20 | 0.94 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.94 |
| ▸ | NQO2 | P16083 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9118982 | 1.00 | MTNR1A (0.94) | MTNR1AMTNR1BNQO2ALDH1A1KDM4E | |
| SCHEMBL9121699 | 0.97 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2ALDH1A1KDM4E | |
| SCHEMBL7017969 | 0.95 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2ALDH1A1 | |
| SCHEMBL7018436 | 0.84 | MTNR1A (0.68) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL7021068 | 0.84 | MTNR1A (0.67) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL7021115 | 0.84 | MTNR1A (0.67) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL7021548 | 0.84 | MTNR1A (0.67) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL7237645 | 0.83 | MTNR1A (0.66) | MTNR1AMTNR1BNQO2ALDH1A1 | |
| SCHEMBL7024784 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2ALDH1A1KDM4E | |
| SCHEMBL7018620 | 0.82 | MTNR1A (0.67) | MTNR1AMTNR1BNQO2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635650-B2 | Such as N-(2-(7-(2-((8-(2-(acetyl-amino)ethyl)-2-naphthyl) oxy)ethoxy)-1-napthyl)ethyl)acetamide for treating or preventing melatoninergic disorders | LES LABORATOIRES SERVIER (FR) | 2003-10-21 | — | — | US | disclosed |
| EP-1038863-B1 | Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2003-06-04 | — | — | EP | disclosed |
| US-20020035114-A1 | Substituted dimeric compounds | LESIEUR DANIEL (FR) | 2002-03-21 | — | — | US | disclosed |
| US-6319930-B1 | CONTAINING FUSED AROMATIC CARBO- OR HETEROCYCLIC RINGS AND AMIDE, THIOAMIDE, UREA OR THIOUREA GROUPS; USEFUL IN TREATING OR IN PREVENTING MELATONINERGIC DISORDERS. | ADIR ET COMPAGNIE (FR) | 2001-11-20 | — | — | US | disclosed |
| EP-1038863-A2 | Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof | ADIR ET COMPAGNIE (FR) | 2000-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035114-A1 | Substituted dimeric compounds | NR0B2, NR0B1, NR2C2 | MTNR1A 4/4885MTNR1B 5/4885NQO2 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.